3SBIO News

Sansheng Pharmaceutical (1530.HK): Medical insurance R&D pipeline progresses at an accelerated pace for multiple product renewals

China Great WallDec 19, 2024 00:00

Major rating｜CITIC International: Slightly raised the target price of 3sbio to HKD 9.81 with a rating of "buy".

Gelonghui FinanceDec 6, 2024 09:59

Sansheng Pharmaceutical (1530.HK): It is expected that Terbi Australia will continue to grow rapidly, and innovative varieties are ready to go

Zhao Yin InternationalDec 5, 2024 00:00

China Merchants: Maintains a "shareholding" rating on 3SBio (01530) with target price raised to HK$11.

Zhitong FinanceDec 3, 2024 10:46

Sansheng Pharmaceutical (1530.HK): Domestic biopharmaceutical pioneers have rich reserves of products under development

china great wall securitiesNov 5, 2024 00:00

Bocom Intl: rates the Mainland pharmaceutical industry as "leading", focusing on innovative and consumer-driven targets.

Zhitong FinanceOct 17, 2024 09:53

Rating by major banks | CICC International: Overseas rate cuts are expected to help the mainland pharmaceutical industry rebound. Bullish on wuxi apptec, innovent bio, etc.

Gelonghui FinanceSep 23, 2024 15:02

Strong Growth and Diversified Portfolio Underpin Buy Rating for 3SBio

TipRanksAug 26, 2024 19:52

3SBIO(1530.HK):SOLID EARNINGS PERFORMANCE IN 1H24

招银国际Aug 26, 2024 14:56

Sansheng Pharmaceutical (01530.HK): 1H24's performance is in line with expectations and maintains steady growth

Aug 25, 2024 18:16

Sansheng Pharmaceutical (01530.HK): Rapid growth in performance, rich R&D pipeline layout

Aug 25, 2024 00:00

Sansheng Pharmaceutical (1530.HK): Achieve rapid release of core products and continue to strengthen innovative research and development

Aug 25, 2024 00:00

3SBIO INC(1530.HK):ADJUSTED NET PROFIT MISSED ON INCREASED R&D EXPENSE

中银国际Aug 23, 2024 20:01

3SBio: Balancing Growth Prospects With Financial Challenges – A Hold Rating by Sean Wu, CFA

TipRanksAug 23, 2024 19:03

Sansheng Pharmaceutical (01530.HK): The growth of core products is impressive, and the self-exemption pipeline continues to progress

Aug 23, 2024 00:00

Sansheng Pharmaceutical (01530.HK): 2024H1 performance is in line with expectations, rich innovative product echelons

Aug 23, 2024 00:00

DBS upgrades the rating of 3sbio (01530) to "in line with the market" and raises the target price to HKD 8.

Zhitong FinanceJul 9, 2024 11:51

Sansheng Pharmaceutical (01530.HK): Approval of ITP indications for children in Terbi Australia is expected to support continued income growth

Apr 12, 2024 00:00

Analysts Offer Insights on Healthcare Companies: 3SBio (OtherTRSBF), UnitedHealth (UNH) and Caribou Biosciences (CRBU)

TipRanksApr 5, 2024 17:50

Sansheng Pharmaceutical (01530.HK): Rapid growth in business performance, strong sales performance in Turbie Australia and Mandy

Mar 28, 2024 07:51